MLTX
HealthcareMoonLake Immunotherapeutics · Biotechnology · $1B
What is MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company focused on developing a novel Nanobody therapy targeting inflammatory diseases. Founded in 2020 and headquartered in Zug, Switzerland, the company has no approved products yet and remains in active clinical development.
MoonLake's pipeline centers on Sonelokimab, an investigational Nanobody designed to block inflammation pathways. The company is advancing this therapy through Phase II clinical trials across several inflammatory conditions, including hidradenitis suppurativa, psoriatic arthritis, and forms of axial spondyloarthritis. As a pre-revenue, clinical-stage company, MoonLake does not yet generate product sales — its value is tied entirely to the clinical and regulatory progress of Sonelokimab.
MoonLake was founded in 2020 and operates from its headquarters in Zug, Switzerland.
- Sonelokimab — investigational Nanobody targeting inflammation
- Phase II trials in hidradenitis suppurativa
- Phase II trials in psoriatic arthritis
- Phase II trials in ankylosing spondylitis and axial spondyloarthritis
Is MLTX a Good Stock to Buy?
UQS Score rates MLTX as Poor overall, reflecting the early-stage nature and inherent uncertainties of a clinical-stage biopharmaceutical company.
Among the five pillars, Risk stands out as the relative bright spot — suggesting the company's financial structure carries a degree of resilience compared to what might be expected at this development stage.
Quality, Moat, and Growth all register as Weak, which is typical for pre-revenue biotechs with no approved products. Valuation is rated Elevated, meaning the current market price reflects significant future expectations that have yet to be validated by clinical outcomes.
Pro members can view the complete pillar breakdown and underlying financial metrics to understand exactly where MLTX stands across all five dimensions. Sign up free →
Past performance does not guarantee future results. UQS Score is based on fundamental data and is not a buy/sell recommendation.
Does MLTX pay dividends?
No — MoonLake Immunotherapeutics does not currently pay a dividend.
MLTX does not pay a dividend, which is standard for clinical-stage biotechs. All available capital is directed toward funding ongoing clinical trials and advancing Sonelokimab through development. Income-focused investors should not expect distributions from MoonLake at this stage of its lifecycle.
When does MLTX report earnings?
MoonLake Immunotherapeutics reports financial results on a quarterly cadence, consistent with US-listed equities.
As a pre-revenue company, MoonLake's quarterly reports focus on cash runway, operating expenses, and clinical trial progress rather than traditional revenue or profit metrics. Investors typically watch for updates on trial enrollment and interim data readouts.
For the most recent quarter's results and clinical updates, visit MoonLake Immunotherapeutics' investor relations page directly.
MLTX Price History
+72.2% over 5Y
Monthly close, adjusted for stock splits and dividend reinvestment.
What if I invested in MoonLake Immunotherapeutics?
Based on MoonLake Immunotherapeutics's historical closing prices, adjusted for stock splits and dividend reinvestment. Past performance does not guarantee future results. This is for informational purposes only and is not financial advice.
MLTX Long-term Outlook
The fundamental outlook for MLTX is shaped primarily by clinical execution risk. With Growth and Quality both rated Weak, the near-term trajectory depends almost entirely on whether Sonelokimab delivers meaningful Phase II data. The Risk pillar rating of Good provides some comfort around financial stability, but an Elevated Valuation rating suggests the market has already priced in optimistic scenarios — leaving limited margin for clinical disappointment.
Growth drivers
- Positive Phase II readouts for Sonelokimab across multiple indications
- Potential to address large unmet need in inflammatory disease markets
- Nanobody platform differentiation versus conventional biologics
Key risks
- Clinical trial failure or unfavorable safety data for Sonelokimab
- Elevated valuation leaves little room for setbacks
- Dependence on a single investigational asset with no approved products
MLTX vs Peers
MoonLake operates in a competitive clinical-stage biotech landscape alongside other development-stage companies pursuing novel biologics.
Bicara focuses on bifunctional antibody therapies targeting oncology, distinguishing it from MoonLake's inflammation-focused Nanobody approach.
ArriVent is developing targeted therapies for lung cancer, placing it in a different therapeutic area than MoonLake's inflammatory disease pipeline.
Inhibrx pursues a multi-asset biologic platform across rare diseases, offering broader pipeline diversification compared to MoonLake's single-asset focus.
Frequently Asked Questions
What does MoonLake Immunotherapeutics do?
MoonLake Immunotherapeutics is a clinical-stage biopharmaceutical company developing Sonelokimab, a Nanobody therapy designed to treat inflammatory diseases. The company is currently running Phase II trials across conditions including hidradenitis suppurativa, psoriatic arthritis, and axial spondyloarthritis. It has no approved products and generates no product revenue at this stage.
Does MLTX pay dividends?
No, MLTX does not pay a dividend. Clinical-stage biotechs like MoonLake typically reinvest all available capital into research and clinical development. Investors seeking income should look elsewhere, as dividend payments are not expected until the company reaches commercial-stage operations.
When does MLTX report earnings?
MoonLake reports financial results quarterly, in line with standard US-listed company practice. Because it is pre-revenue, reports focus on operating expenses and cash position rather than sales figures. Check MoonLake's investor relations page for the most current schedule and recent filings.
Is MLTX a good stock to buy?
The UQS Score rates MLTX as Poor overall, driven by Weak ratings across Quality, Moat, and Growth pillars. The Risk pillar is rated Good, but Valuation is Elevated. This profile reflects the high-uncertainty nature of a single-asset clinical-stage biotech. Pro members can access the full pillar breakdown to make a more informed assessment.
Is MLTX overvalued?
The UQS Valuation pillar for MLTX is rated Elevated, indicating the current market price embeds significant optimism about Sonelokimab's clinical success. For a pre-revenue company, this means investors are paying a premium relative to the company's current fundamental profile. The complete valuation metrics are available to Pro members.
How does MLTX compare to its competitors?
MoonLake competes in the broader clinical-stage biotech space alongside companies like Bicara Therapeutics, ArriVent BioPharma, and Inhibrx Biosciences. Unlike some peers with diversified pipelines or oncology focus, MoonLake is concentrated on a single Nanobody asset in inflammatory disease. UQS Score comparisons across these tickers are available on each company's page.
What is MLTX's market cap bracket?
MLTX is classified as a small-cap stock. This places it in a segment of the market typically associated with higher volatility and less analyst coverage than large- or mega-cap peers. Small-cap biotechs can experience outsized price moves around clinical data readouts.
Who founded MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics was founded in 2020. Detailed founding history and leadership background are publicly available through the company's official website and SEC filings for those seeking more context on the founding team.
Is MLTX a long-term quality investment?
As a long-term quality indicator, the UQS Score currently rates MLTX as Poor. The Weak ratings across Quality, Moat, and Growth pillars reflect the absence of revenue, competitive entrenchment, or demonstrated business durability. Long-term quality typically improves if clinical milestones are achieved and the business matures toward commercialization.
What is the main competitive advantage of MoonLake Immunotherapeutics?
MoonLake's potential differentiation lies in its Nanobody technology platform. Nanobodies are smaller than conventional antibodies and may offer advantages in tissue penetration and manufacturing. However, with the Moat pillar rated Weak, the UQS framework does not yet recognize a durable competitive advantage — which is common for pre-approval biotechs.
What sector does MLTX belong to?
MLTX belongs to the Healthcare sector, specifically within the clinical-stage biopharmaceutical segment. This segment is characterized by binary risk events tied to clinical trial outcomes and regulatory decisions rather than traditional revenue-driven business metrics.
Is MLTX a growth stock or value stock?
Based on UQS pillar labels, MLTX does not fit neatly into either category. The Growth pillar is rated Weak — reflecting no current revenue growth — while the Valuation pillar is Elevated, ruling out a value classification. It is best described as a speculative clinical-stage biotech rather than a conventional growth or value investment.
Unlock Full MLTX Analysis
Sign in to unlock the detailed analysis behind the UQS Score.
- ✓See the exact UQS Score and all five pillar scores
- ✓View underlying financial metrics driving each pillar
- ✓Compare MLTX against sector peers side by side
- ✓Access the complete risk and valuation breakdown
- ✓Track score changes as new data becomes available
Pro Analysis
MLTX — Score History
| Date | UQS | Quality | Moat | Growth | Risk | Value | Change |
|---|---|---|---|---|---|---|---|
| May 22, 2026 | 13.2 | 0.0 | 13.0 | 0.0 | 66.5 | 0.0 | +3.0 |
| May 9, 2026 | 10.2 | 0.0 | 13.0 | 0.0 | 46.2 | 0.0 | -2.7 |
| Apr 2, 2026 | 12.9 | 0.0 | 13.0 | 0.0 | 64.2 | 0.0 | — |
MLTX — Pillar Breakdown
Quality
— 0.0/100 (25%)MoonLake Immunotherapeutics currently shows below-average quality metrics, suggesting challenges with profitability.
How effectively capital is deployed to generate returns.
Profitability relative to shareholders' equity.
Ability to convert revenue into operating profit.
Bottom-line profit as a share of revenue.
Free cash flow relative to market value.
Growth
— 0.0/100 (20%)MoonLake Immunotherapeutics faces growth headwinds with declining or stagnant revenue trends.
Revenue trajectory over the last twelve months.
Year-over-year earnings per share growth.
Analyst consensus for future revenue growth.
Risk
— 66.5/100 (15%)MoonLake Immunotherapeutics maintains a reasonable risk profile with manageable debt levels.
Debt levels relative to earnings capacity.
Total debt relative to shareholder equity.
Short-term liquidity — ability to pay near-term obligations.
Earnings capacity relative to interest payments.
Valuation
— 0.0/100 (15%)MoonLake Immunotherapeutics appears expensively valued relative to its fundamentals and growth prospects.
Moat
— 13/100 (25%)MoonLake Immunotherapeutics operates in a highly competitive environment with limited sustainable advantages. The Moat pillar evaluates competitive advantages across five dimensions: Switching Costs, Network Effects, Cost Advantage, Intangible Assets, and Scale & Ecosystem. Sign in to customize moat ratings for MLTX.
Score Composition
Financial Data
More Stock Analysis
How is the MLTX UQS Score Calculated?
The UQS (Unified Quality Score) for MoonLake Immunotherapeutics is calculated using a proprietary 6-pillar framework with 29 financial metrics. Each pillar evaluates a different dimension on a 0–100 scale, then combines into a single weighted score. Scoring thresholds are calibrated per sector. Momentum is an optional Pro toggle — without it, you get the 5-pillar / 25-metric core shown below.
Quality (25%) measures profitability and capital efficiency — ROIC, ROE, margins, GP/Assets, and FCF Yield.
Moat (25%) assesses MoonLake Immunotherapeutics's competitive advantages across switching costs, network effects, cost advantages, intangible assets, and ecosystem scale.
Growth (20%) tracks revenue trajectory and earnings momentum, combining historical results with analyst forward estimates.
Risk (15%) is inversely scored — lower leverage and strong balance sheet health result in higher scores.
Valuation (15%) measures whether MoonLake Immunotherapeutics is fairly priced using earnings yield, price-to-FCF, PEG ratio, and EV/EBITDA relative to sector peers.
Six investor-inspired presets are available, each with different pillar weights: Balanced, Buffett, Munger, Lynch, Cathie Wood, and Graham. The public score shown here uses the Balanced preset. Learn more in our FAQ.